PTU - Polskie Towarzystwo Urologiczne
list of articles:

Article published in Urologia Polska 1997/50/4.


Anna Kołodziej, Danuta Duś, Janusz Dembowski, Tadeusz Niezgoda, Bogdana Dąbrowska, Jerzy Lorenz
Katedra i Klinika Urologii AM we Wrocławiu
Kierownik Kliniki: prof. dr hab. med. Jerzy Lorenz
Oddział Urologii Wojewódzkiego Szpitala Specjalistycznego we Wrocławiu
Ordynator: prof. dr hab. med. Jerzy Lorenz
Zakład Immunologii Nowotworów
Instytutu Immunologii i Terapii Doświadczalnej PANwe Wrocławiu
Kierownik: prof. dr hab. Cz. Radzikowski


bladder neoplasms DNA ploidy


Objective. The aim of the study was to find the correlation between DNA
ploidy as a tumor marker and the stage, the histopatologie grade and clinical
course of the disease in bladder cancer patients.
Material and method. A prospective study of cellular DNA content by flow
cytometry was performed on bladder irrigation and tissue obtained from 105
patient with urothelial bladder carcinoma.
Results. The DNA histogram were classified as diploid (52/105) and
aneuploid (53/105) with one or more aneuploid cell population. While grade
1 transitional cell carcinoma were with few exceptions diploid and grade 3
aneuploid, about half of grade 2 tumors were diploid or aneuploid. A significant
correlations were found: beetwen T category and DNA ploidy - invasive tumors
were aneuploid, beetwen type of growth and multiplicity of tumors. The results
of DNA measurement were also related to the clinical course of the disease:
patients with diploid tumors had very low receurence rate and developed
almost no progression (mean follow - up 22 months).
Conclusions. The results of prospective studies of flow cytometry DNA
analysis indicate DNA ploidy status as a useful complement to the clinical
and histological classifications of urothelial bladder carcinoma.


  1. [1] Abel, P. D., Henderson, D., Bennett, M. R.: Differing interpretations bypatho-
  2. logists of the T category and grade of transitional cell cancer of the bladder. Br. J.
  3. Urol., 1988, 62, 339-343.
  4. [2] Badalament, R., Kimmel, H., Gay, H., i wsp.: Thesensitivity oj'flow cytometry
  5. compared with conventional cytology in the detection of superficial bladder carcino-
  6. ma. Cancer, 1987, 59, 2078-2083.
  7. [3] Borkowski, A.: Leczenie powierzchownych nowotworów pęcherza moczowego. Uro-
  8. logia 1989, 21. Oddział Warszawski PTU Warszawa 1990.
  9. [4] Campanella, R., Russo, A., Pavone-Macaluso, M., i wsp.: Study of cellular DNA
  10. content by flow cytometry in primary bladder carcinomas. Eur. Urol., 1992,21,58-62.
  11. [5] De Vere White, R. W., Deith, A., West, B., i wsp.: Thepredictivevalueofflow
  12. cytometric information in the clinical management of stage O (Ta) bladder cancer. ].
  13. Urol., 1988, 139, 279-282.
  14. [6] Devonec, M.: Une nouvelle hypothese sur 1'histoire naturelle du cancer de la vessie
  15. grace a 1'etude du contenu en ADN des tumeurs par la cytometrie enflux. Ann. Urol,
  16. 1987, 21, 250-254.
  17. [7] Giella, J. G., Ring, K., Olsson, C. A., i wsp.: The predidwe value of flow
  18. cytometry and urinary cytology in the follow-up patients with transitional cell
  19. carcinoma of the bladder. J. Urol., 1992, 148, 293-297.
  20. [8] Gustaffson, H., Tribukait, B.: The prognostic value of flow DNA. A follow-up
  21. study. Precedings WHO Conference on urinary bladder cancer. Stockholm,
  22. 1982.
  23. [9] Henney, N. M., Alimed, S., Flanayer, M., i wsp.: National Bladder Cancer
  24. Collaborative group A: Superficial bladder cancer progression and reccurence.
  25. J. Urol., 1983,130,1083-1088.
  26. [10] Klein, F. A., Herr, H. W., Melamed, M.: Flow cytometry follow-up of pa-
  27. tients with low stage bladder tumors. J. Urol., 1982,126, 88-92.
  28. [11] Lieskovsky, G., Skinner, D. G.: Role of lymphadenectomy in the treatment of
  29. bladder cancer. Urol. Clin. N. Amer., 1989,11, 4, 709-713.
  30. [12] Melamed, M. R., Staiano-Coico, L.: Flow cytometry in clinical cytology. Flow
  31. cytometry and sorting. Second edition. 755,1990 Wiley-Liss, Inc.
  32. [13] Sherman, C. D.: Onkologia kliniczna. PZWL, Warszawa, 1992.
  33. [14] Skinner, D. G., Richie, J. P., Cooper, P. H., i wsp.: The clinical signiofican-
  34. ce of carcinoma in situ of the bladder and its association with overt carcinoma.
  35. J. Urol., 1974,112, 68-72.
  36. [15] Skinner, D. G., Lieskovsky, G.: Contemporary cystectomy with pelvic node
  37. dissection compared to preoperatve radiation therapy plus cystectomy in managa-
  38. ment of invasive bladder carcinoma. J. Urol, 1984, 131, 1069-1073.
  39. [16] Stockle, M., Steinbach, F., Voges, G., Hohenfellner, R.: Image analysis
  40. DNA cytometry of bladder tumor. Recent Results in Cancer Res., 1993, 126,
  41. 151-155.
  42. [17] Stokłosa, A., Sikora, A., Borkowski, A., i wsp.: Ploidia DNA a inne czyn-
  43. niki ryzyka progresji w powierzchownych nowotworach pęcherza moczowego. XXIII
  44. Zjazd Naukowy PTU, Szczecin 14-16 X 1993, Urol. Pol. Supl, 63.
  45. [18] Tavar, A. S., Costa, J., Reis, M.: Tumor ploidy and prognosis in carcinoma of
  46. the bladder cancer and prostatae. Br. J. Cancer, 1966, 20, 438-442.
  47. [19] Tribukait, B.: Flow cytometry in assesing the clinical agressivenes of genitouri-
  48. nary neoplasm. Word J. Urol. 1987, 5, 108-111.
  49. [20] Wheeles, L. L., Badalament, R. A., De Vere White, R., Tribucait, B.:
  50. Consensus review of the clinical utylity of DNA cytometry in bladder cancer. Cy-
  51. tometry, 1993, 14, 478-483.
  52. [21] Zatoński, W.: Nowotwory złośliwe w Polsce w 1989 roku. ZOWzRiEN, War-
  53. szawa 1992.
  54. [22] Zieliński, J.: Onkologia urologiczna. PZWL Warszawa 1986.